Overview

Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS)

Status:
Active, not recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of combined chemotherapy and radiotherapy (in comparison to chemotherapy alone) as adjuvant treatment after surgery for gastric cancer. Prior to surgery all patients will receive neo-adjuvant chemotherapy as well.

Phase:

Phase 3

Details

Lead Sponsor:

Dutch Colorectal Cancer Group

Collaborators:

Roche Pharma AG
The Netherlands Cancer Institute

Treatments:

Capecitabine
Cisplatin
Epirubicin